Developer of biological detection and diagnostics solutions, PositiveID Corp(OTCMKTS:PSID), has announced that it filed an additional U.S. patent for the Firefly Dx real-time PCR (polymerase chain reaction) pathogen detection system which is known as, “A Cyclical PCR Device with Reusable Heat Zones.”
This has brought the number of patents pending for Firefly Dx to four and the firm’s total number of patents pending to 18.
Firefly Dx is made to give real-time and precise diagnostic results using PCR chemistry in a device held by hand which leads to treatment scenarios at the point of need which that are not possible with existing systems. The existing ones need lab-based equipment and may take days or hours to give results.
The new patent application will give results in less than 20 minutes whereas it still utilises standard laboratory volumes and processes in an automated cartridge.
According to a Research and Markets’ report Polymerase Chain Reaction (PCR) – Products/Tools – A Global Market Watch, 2009-2015, Firefly Dx is looking at the PCR market globally that is projected to reach $27.4 billion in the Current year.
The firm’s applications include agricultural screening in both developing countries and domestic sectors, point of need monitoring of pathogenic outbreaks such as in case of Ebola and for detection of biological agents related to weapons of mass destruction.
William J. Caragol, Chairman and CEO of PositiveID stated that the company will continue to make the intellectual property position stronger for Firefly Dx as the testing and development of system progresses.
He added that the firm would be able to come out with an optimistic result within 20 minutes using the Firefly PCR chip and that it is confident that the technology would not just work but also ensure a paradigm shift for the broader market.
PositiveID Corporation is a developer of biological detection systems for America’s homeland defense industry and an emerging growth company.